Related Experiment Video
Updated: Jun 26, 2026

Preparation, Purification, and Characterization of Lanthanide Complexes for Use as Contrast Agents for Magnetic Resonance Imaging
Published on: July 21, 2011
[Pharmacodynamic and pharmacokinetic profile of lanthanum carbonate]
1Toho University Ohashi Medical Center, Division of Nephrology.
Abstract:
Lanthanum (La) is a rare-earth element in transition Group III b of the periodic table. It is a ductile and malleable, silvery-white metal, soft enough to be cut with a knife. Lanthanum carbonate (La2[CO3]3) is the most recent non-calcium, non-aluminum phosphate binder to be developed for the treatment of hyperphosphatemia. This drug has already been registered and available in the US and EU. Precilinical studies have shown that it is as effective as aluminium, without the associated toxicity, and is minimally absorbed. In clinical studies (La2[CO3]3) has a similar ability to calcium carbonate in controlling serum phosphate level without hypercalcemia. In this review I would like to summarize the pharmacodynamic and pharmacokinetic profile of this new phosphate binder (La2[CO3]3) which will be registered in our country in the near future.
Related Concept Videos
Pharmacodynamic Models: Logarithmic Concentration–Effect Model
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
Pharmacokinetic–Pharmacodynamic Relationship: Dose to Pharmacological Effect
Pharmacodynamic Models: Linear Concentration–Effect Model
Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model
Nonlinear Pharmacokinetics: Overview
Nonlinearity can arise due to the saturation of plasma protein-binding or...
